French pharmaceutical logistics company, Walden, has purchased Ivemar to support its subsidiary, Transpharma International, and grow its European fleet.
“The acquisition of Ivemar provides Transpharma International with transport assets, a strong team well practised in GDP and licensed premises located in a key European trade corridor for transport and logistics,” said Transpharma CEO, David Evans.
Transpharma International specialises in first-mile pharmaceutical transport and global freight forwarding. The addition of the Ivemar fleet will grow its European fleet to more than 250 vehicles, offering pan-European temperature-controlled transport for shipments.
The acquisition, Walden said, will also develop its capability for in-transit storage and cross-docking at licensed warehouse locations close to Brussels, and the addition of licensed and temperature-controlled storage at Brussels airport.
The addition of storage capacity directly at the aircraft exit now enables Transpharma International to strengthen its service and it can now offer temperature-controlled storage solutions for goods in transit, as well as storage of supply flows to manufacturers from and to the rest of the world.
The founder and CEO of Ivemar, Yves Smets, said he was delighted to see the company joining Walden Group.
“Our expertise and infrastructure are the perfect complement to Transpharma International’s network and capabilities,” he said. “It’s a great opportunity to bring additional expertise to the group.”